10x Genomics, Inc. · NASDAQ:TXG
10x Genomics — 42nd Annual J.P. Morgan Healthcare Conference (January 2024)
32 slides from 10x Genomics's conference presentation, Jan 8, 2024
Slide 1: Accelerating the Mastery of Biology to Advance Human Health
Accelerating the Mastery of Biology to Advance Human Health 42nd Annual J.P. Morgan Healthcare Conference Serge Saxonov CEO and Co-founder
Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain statements in this presentation and the accompanying oral commentary are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E o
Slide 3: Leading the Single Cell and Spatial Biology Revolution
Leading the Single Cell and Spatial Biology Revolution 2023 Revenue Publications Patents / Applications Instruments Sold ~$619M 7,100+ ~2,200 5,900+ +20% +58% +25% +27% Note: 2023 revenue represents preliminary and unaudited results. Publications, patents and applications, and cumulative instruments
Slide 4: Robust Revenue Growth
Robust Revenue Growth Q4 2023 ~$184M 18% ~$49M Revenue Y/Y Growth Spatial Revenue Full Year 2023 ~$619M 20% ~$135M Revenue Y/Y Growth Spatial Revenue Note: Q4 and 2023 revenue represents preliminary and unaudited results. Growth rates represent year-over-year growth compared to December 31, 2022. ©
Slide 5: An Exceptional Launch Year for Xenium
An Exceptional Launch Year for Xenium Rapid customer adoption and operational ramp Just one year since launch! Rapidly scaled operations and manufacturing capacity Field teams dedicated to customer success from install to insight Multiple customers with repeat Xenium instrument orders © 10X GENOMICS
Slide 6: An Exceptional Launch Year for Xenium
An Exceptional Launch Year for Xenium Incredible customer enthusiasm "The Xenium platform is providing "It works like a charm, does the us with unprecedented insight into job as per specs and beyond. the molecular pathology of disease As I said it before, it's a cut at an incredible resolution." abo
Slide 7: An Exceptional Launch Year for Xenium
An Exceptional Launch Year for Xenium Validated by leading independent researchers as the best performing in situ platform More Sensitive More Specific Higher Throughput 3–5x 3–4x 1 1 3 3–14x Better than MERSCOPE Better than MERSCOPE Faster than CosMx 2–15x 1 30–45x 1, 2 Better than CosMx Better tha
Slide 8: An Exceptional Launch Year for Xenium
An Exceptional Launch Year for Xenium Early customer success, from install to insight © 10X GENOMICS, INC. 2024 8
Slide 9: Century of Biology
Century of Biology 9
Slide 10: Biology is Immensely Complex
Biology is Immensely Complex Enormous complexity within each cell Interactions of millions of different molecules and molecular machines 40 trillion cells in the human body Each cell contains its own set of expressed genes Cells form tissues which form organs Each tissue comprises a large diversity
Slide 11: Proven Innovation Engine
Proven Innovation Engine Xenium Panels Flex + Proteins Visium + Proteins $1.5B+ ~2,200 Xenium Platform Visium CytAssist Invested in Patents and Single Cell Gene Chromium X R&D to Date Applications Series Expression Flex Chromium 10x Cloud 25+ Connect Multiome Visium FFPE Breakthrough Next GEM Produc
Slide 12: Scaled for Long-Term Growth and Impact
Scaled for Long-Term Growth and Impact Broad Commercial Reach ~450 Commercial 175+ Commissionable 170+ Field and Technical 39 Authorized Employees Salesforce Support Specialists Distributors Robust Operational Scale ~250 Operations Scalable 3 2.8x Increase in >4x Capacity for Growth Employees Manufa
Slide 13: Three Platforms to Resolve Biology's Complexity
Three Platforms to Resolve Biology’s Complexity Chromium Single Cell Visium Spatial Xenium In Situ NGS-Based NGS-Based Imaging-Based © 10X GENOMICS, INC. 2024 13
Slide 14: Chromium Single Cell Platform
Chromium Single Cell Platform Market-Defining Platform ● Catalyzed Single Cell revolution ● Broad menu of assays, analytes and applications ● High performance, quality of data and ease of use ● Extensive ecosystem of customers, datasets, protocols and papers ~$468M 6,500+ 5,150+ 2023 Chromium Chromi
Slide 15: Visium Spatial Platform
Visium Spatial Platform The Leader in Spatial Discovery ● The platform for unbiased spatial analysis ● Bridges worlds of histology and genomics ● Visium CytAssist delivers best-in-class experience ● Compatibility with archival slides enables large-scale studies 500+ 400+ 2,900+ Cumulative Peer-Revie
Slide 16: Xenium In Situ Platform
Xenium In Situ Platform The In Situ Performance Leader ● Independently validated as the best performing In Situ platform ● Fully integrated system with easy-to-run workflow ● Onboard analysis and intuitive software to immediately access data ● Customizable, biologically relevant content panels ● Com
Slide 17: 10x Platforms Produce Complementary Data
10x Platforms Produce Complementary Data Chromium Single Cell Visium Spatial Product Ecosystem Xenium In Situ © 10X GENOMICS, INC. 2024 17
Slide 18: All Tissues Are Heterogeneous and Complex
All Tissues Are Heterogeneous and Complex t-SNE2 © 10X GENOMICS, INC. 2024 18
Slide 19: Replacing the Legacy Toolkit Across Life Sciences
Replacing the Legacy Toolkit Across Life Sciences Resolution: spatial & cellular insights IF & Flow ISH cytometry IHC High High-content imaging & cell-based assays PCR/qPCR Low ELISAs Western Bulk next-gen blots sequencing Low High Scale of measurements: plexy, number of analytes © 10X GENOMICS, INC
Slide 20: Revolutionizing How Researchers Address Biological Questions
Revolutionizing How Researchers Address Biological Questions Genetic Cellular & Atlassing Translational Mechanisms Molecular Biology $2B $2B $5B $7B Identify cellular & Determine role of Understand functions of Apply biological molecular building genetics in biological specific gene, protein or lear
Slide 21: Robust Growth in Atlassing
Robust Growth in Atlassing More Atlassing; More Insights Focus of Multiple Consortia Human Diversity $155M HCA-Related Funding Development and Disease $500M Spatial Effort Multiomics $130M Effort to Date Transcriptomics $190M Initial 5-year Investment © 10X GENOMICS, INC. 2024 21
Slide 22: Significant Opportunity in Translational Applications
Significant Opportunity in Translational Applications Growing translational traction… …accelerated by the right products New Large-Scale Multiomic Partnership Chromium Flex ~7,000 Tumor Samples Cross-Platform ~30% In translational publications or pre-prints citing 10x tools FFPE Compatibility Y/Y In
Slide 23: Market Growth Drivers
10x technology innovation to drive adoption by 1 delivering better insights, workflows and cost structure Expansion of single cell approaches into more areas 2 of academic research Market Growth 3 Adoption of single cell in translational and biopharma applications Drivers 4 Continued momentum in spa
Slide 24: Future Product Development Directions
Future Product Development Directions Measure More Biology Improve Ease of Use Lower Cost ● More analytes, applications ● Workflow robustness, experimental ● Lower cost per cell, tissue and multiomics logistics area, sample, experiment ● Higher resolution, sensitivity ● Sample prep, sample breadth a
Slide 25: Chromium Product Development Directions
Chromium Product Development Directions Cell Throughput Sensitivity Recovery and Scale Ease of Use Applications … and lowering cost Raising the bar on performance… toward $100/sample 2024 and beyond © 10X GENOMICS, INC. 2024 25
Slide 26: Upcoming Xenium Product Roadmap
Upcoming Xenium Product Roadmap Multimodal ~5,000 Plex Panels In-line Multiplex 1,000–2,000 Plex Segmentation ~5-day run Protein Panels Broad compatibility High quality data Same slide as RNA Offers more flexibility Shipping Q1 Q2 2024 H2 2024 2024+ Note: Final product release timelines and configur
Slide 27: Visium Innovation: Major Recent Advances
Visium Innovation: Major Recent Advances Launched Visium CytAssist for best-in-class experience Launched Visium Gene Expression + Protein, on the same section Enabled archival slide compatibility Launched Visium FFPE v2 for improved performance © 10X GENOMICS, INC. 2024 27
Slide 28: Visium HD: A Revolution in Resolution
Visium HD: A Revolution in Resolution Visium Visium HD 2 µm squares no gaps 55 µm spots 2 µm squares Hexagonally arranged Continuous grid-pattern 5,000 11,000,000 features features © 10X GENOMICS, INC. 2024 28
Slide 29: Visium HD Will Generate Stunning Data
Visium HD Will Generate Stunning Data Visium Visium HD © 10X GENOMICS, INC. 2024 29
Slide 30: Visium HD: Broad Range of Samples
Visium HD: Broad Range of Samples Human Mouse Embryo Lung Brain normal Colon, normal Ovarian cancer Tonsil Brain Small intestine Breast, normal Spleen Prostate cancer Pancreas Breast cancer Lung cancer Skin melanoma Liver cancer Kidney Heart © 10X GENOMICS, INC. 2024 30
Slide 31: Order Today: Visium HD Shipping This Quarter
Order Today: Visium HD Shipping This Quarter ● Unparalleled spatial discovery: Whole transcriptome gene expression analysis ● Resolved at single cell scale: Capture Area with grid-patterned 2 x 2 µm barcoded squares ● High data quality: Precise instrument-driven probe capture ● Broad access to diver
Slide 32: See you at the AGBT General Meeting!
See you at the AGBT General Meeting! February 5–8, 2024 | Orlando, Florida
10x Genomics — 42nd Annual J.P. Morgan Healthcare Conference (January 2024) on 6ix